Répertoire du corps professoral

Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial
Organisme(s) subventionnaire(s): Procure Alliance
Type de financement: Subvention
Établissement tête: Université Laval
Du 17 juin 2024 au 16 juin 2025

Analyse des vésicules extracellulaires dans le sang des hommes atteints d’un cancer de la prostate : utilité dans la stadification de la maladie et la réponse au traitement.
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mai 2024 au 1 mai 2027

Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 31 mars 2023 au 31 mars 2025

Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2022 au 30 septembre 2027

Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes
Programme: Fonds des leaders John-R.-Evans (FLJR)
Organisme(s) subventionnaire(s): Ministère de la Santé et des Services sociaux, Fondation du CHU de Québec, Fondation Canadienne pour l'innovation (La)
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2022 au 30 juin 2025

Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2022 au 31 mars 2027

Projet de recherche sur le cancer de la prostate intitulé Ironman
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 24 mars 2020 au 31 mars 2025

Surveillance of Complex Renal Cysts: The SOCRATIC study
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université de Sherbrooke
Du 1 octobre 2019 au 30 septembre 2028

3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer)
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 7 mars 2018 au 31 mars 2029

Financements des 2 dernières années

Imagerie moléculaire relié au cancer de la prostate
Organisme(s) subventionnaire(s): Fondation de l'Université Laval
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 février 2023 au 31 janvier 2024

Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques
Programme: Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2019 au 30 juin 2023

Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée
Programme: ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université de Sherbrooke
Du 1 avril 2018 au 30 juin 2023

National Program on Radioligand Therapy for Prostate Cancer
Organisme(s) subventionnaire(s): Cancer de la prostate Canada
Type de financement: Subvention
Établissement tête: BC Cancer Agency
Du 1 janvier 2018 au 31 décembre 2022

Encadrements terminés dans les 5 dernières années

Danahé LeBlanc, Maîtrise en physique - physique médicale - avec mémoire

Sébastien Le Batteux, Doctorat en microbiologie-immunologie

Audrey Champagne, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

Response to the Letter to the Editor The Prostate, 2024/11. Nawar Touma, Frederic Pouliot. DOI 10.1002/pros.24783

Rediscovering citrate as a biomarker for prostate cancer Nature Reviews Urology, 2024/10. Lucas Galey, Ayokunle Olanrewaju, Hermann Nabi, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-024-00899-3

Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database Current Oncology, 2024/08/18. Changsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, Lori Wood, Georg A. Bjarnason, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frederic Pouliot, Christian K. Kollmannsberger, Dominick Bosse, Naveen S. Basappa, Antonio Finelli, Nazanin Fallah-rad, Rodney H. Breau, Aly-Khan A. Lalani, Simon Tanguay, Jeffrey Graham, Ramy R. Saleh. DOI 10.3390/curroncol31080351

An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells Biosensors, 2024/04/05. Audrey Champagne, Imene Chebra, Pallavi Jain, Cassandra Ringuette Goulet, Annie Lauzier, Antoine Guyon, Bertrand Neveu, Frédéric Pouliot. DOI 10.3390/bios14040175

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice Current Oncology, 2024/03/07. Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad. DOI 10.3390/curroncol31030106

Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now European Urology, 2023/10. Frédéric Pouliot, Louise Emmett. DOI 10.1016/j.eururo.2023.07.007

Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo Nature Reviews Urology, 2023/08. Lucas Germain, Camille Lafront, Virginie Paquette, Bertrand Neveu, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-023-00726-1

Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy The Prostate, 2023/05. Jérémie Beck, Mélanie Rouleau, Francis Lemire, Bertrand Neveu, Michel Déry, Benoît Thériault, Gabriel Dubois, Dominique Guérette, Frédéric Pouliot. DOI 10.1002/pros.24501

Supplementary Appendix from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480893

Supplementary Appendix from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480893.v1

Figure S2 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480896

Figure S2 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480896.v1

Figure S1 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480902

Figure S1 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480902.v1

Data from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.c.6530550

Data from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.c.6530550.v1

Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level Journal of Urology, 2022/12. Mélanie Rouleau, Bertrand Neveu, Patrick Caron, Fannie Morin, Paul Toren, Louis Lacombe, Véronique Turcotte, Éric Lévesque, Chantal Guillemette, Frédéric Pouliot. DOI 10.1097/JU.0000000000002923

Ultrasound Correlates Highly with Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. Urology, 2022. DOI 10.1016/j.urology.2022.02.020

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022. DOI 10.1002/ctm2.581

Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical genitourinary cancer, 2022. DOI 10.1016/j.clgc.2021.11.018

Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7760

Canadian Urological Association guideline: Management of small renal masses - Full-text. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7763

A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy. Theranostics, 2022. DOI 10.7150/thno.63744

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.12.003

ULTRASOUND CORRELATES HIGHLY WITH CROSS SECTIONAL IMAGING FOR SMALL RENAL MASSES IN A CONTEMPORARY COHORT: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION Journal of Urology, 2021.

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15458

The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized? Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.05.026

The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU international, 2021. DOI 10.1111/bju.15621

TGFβ Signaling in the Tumor Microenvironment. Advances in experimental medicine and biology, 2021. DOI 10.1007/978-3-030-47189-7_6

Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7347

Reply by Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001698.02

Reply by Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001946.03

Reply By Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230.03

Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6779

Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner. Molecular & cellular proteomics : MCP, 2021. DOI 10.1016/j.mcpro.2021.100064

Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.08.016

Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6833

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.4500

PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.5023

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.33

PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 2021. DOI 10.3390/cancers13164023

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European urology focus, 2021. DOI 10.1016/j.euf.2021.10.004

Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.327

Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.02.025

Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021. DOI 10.3390/ijms22189757

Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001517

Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15560

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. DOI 10.1158/1078-0432.CCR-20-4573

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7355

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7357

CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL Journal of Urology, 2021.

Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers, 2021. DOI 10.3390/cancers13215461

Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 2021. DOI 10.1016/j.urology.2021.05.053

Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.05.004

Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. World journal of urology, 2021. DOI 10.1007/s00345-020-03349-y

A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.32

A prospective phase 2/3 study of PSMA-targeted F-18-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.e17003

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.TPS187

A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region Journal of Nuclear Medicine, 2021.

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). The Journal of urology, 2021. DOI 10.1097/JU.0000000000001698

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7074

18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7107

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. The Journal of urology, 2020. DOI 10.1097/JU.0000000000000809

Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2020.

Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians Journal of Clinical Oncology, 2020.

Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2020.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet. Oncology, 2020. DOI 10.1016/S1470-2045(20)30436-8

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426 Journal of Clinical Oncology, 2020.

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. Urologic oncology, 2020. DOI 10.1016/j.urolonc.2020.07.021

OUTCOMES OF RADIOTHERAPY PLUS IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM (CKCis) Radiotherapy and Oncology, 2020.

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European urology oncology., 2020. DOI 10.1016/j.euo.2019.01.009

Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2020.

Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR) Journal of Clinical Oncology, 2020.

HOW WELL DOES RENAL MASS SIZE MEASURED BY ULTRASOUND CORRELATE WITH MEASUREMENTS OBTAINED BY CT, MRI OR PATHOLOGY? ANALYSIS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM Journal of Urology, 2020.

Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. Drug metabolism and disposition: the biological fate of chemicals, 2020. DOI 10.1124/dmd.119.088229

Ga-68-PSMA-617: from gallium production by cyclotron to clinical application Journal of Nuclear Medicine, 2020.

Ga-68-PSMA-617: cellular evidence supporting later acquisition of PET images Journal of Nuclear Medicine, 2020.

GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate cancer and prostatic diseases, 2020. DOI 10.1038/s41391-020-0202-x

GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome Journal of Clinical Oncology, 2020.

First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B Journal of Clinical Oncology, 2020.

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A Journal of Clinical Oncology, 2020.

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. The Journal of urology, 2020. DOI 10.1097/JU.0000000000000699

Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence? Urologic oncology, 2020. DOI 10.1016/j.urolonc.2020.06.001

Diagnostic Performance of PSMA-Targeted F-18-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study Journal of Nuclear Medicine, 2020.

Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. DOI 10.5489/cuaj.6716

Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy Journal of Clinical Oncology, 2020.

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. DOI 10.5489/cuaj.6384

CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL Journal of Urology, 2020.

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. Clinical oncology (Royal College of Radiologists (Great Britain)), 2020. DOI 10.1016/j.clon.2019.07.010

A transcriptionally enhanced biosensor to detect and monitor biopsy-dissociated primary prostate cancer single cell drug responses by bioluminescence microscopy Cancer Research, 2020. DOI 10.1158/1538-7445.Am2020-2015

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. DOI 10.5489/cuaj.6862

A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT Journal of Clinical Oncology, 2020.

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castrationresistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) Journal of Clinical Oncology, 2020.

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) Journal of Clinical Oncology, 2020.

A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL Journal of Urology, 2020.

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. DOI 10.5489/cuaj.6667

Validation of Ga-68-4HMSA-PSMA, a novel PSMA radioligand for PET Imaging of Prostate Cancer Journal of Nuclear Medicine, 2019.

Validation of Ga-68 -Ga-DOTA-TATE using Ga-68 produced by cyclotron Journal of Nuclear Medicine, 2019.

The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy Journal of Nuclear Medicine, 2019.

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-Fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. DOI 10.2967/jnumed.118.225185

Results from the OSPREY trial A PrOspective Phase 2/3 Multi-Center Study of F-18-DCFPyL, PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY Journal of Nuclear Medicine, 2019.

Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. BMJ open, 2019. DOI 10.1136/bmjopen-2018-025662

Renal cell carcinoma in the Canadian Indigenous population. Current oncology (Toronto, Ont.), 2019. DOI 10.3747/co.26.4707

RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT? Journal of Urology, 2019.

Prospective, Multisite, International Comparison of F-Fluoromethylcholine PET/CT, Multiparametric MRI, and Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. DOI 10.2967/jnumed.118.220103

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. The Prostate, 2019. DOI 10.1002/pros.23901

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine, 2019. DOI 10.1056/NEJMoa1816714

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.4500

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.7_suppl.543

ONCOLOGICAL OUTCOMES OF PATIENTS WITH SPORADIC, NON-METASTATIC RENAL CELL CARCINOMA WITH RENAL VEIN OR INFERIOR VENA CAVA TUMOR THROMBUS Journal of Urology, 2019.

Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. Urologic oncology, 2019. DOI 10.1016/j.urolonc.2019.05.009

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019. DOI 10.5489/cuaj.6176

KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC) Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.4569

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. European urology focus, 2019. DOI 10.1016/j.euf.2018.03.008

IMPACT OF TIME-TO-SURGERY AND SURGICAL DELAY ON ONCOLOGIC OUTCOMES FOR RENAL CELL CARCINOMA Journal of Urology, 2019.

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.4570

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.7_suppl.546

Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine connections., 2019. DOI 10.1530/EC-18-0476

Diagnostic performance of F-18-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of F-18-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC) Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.5012

Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic oncology, 2019. DOI 10.1016/j.urolonc.2019.06.006

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells. International journal of molecular sciences, 2019. DOI 10.3390/ijms20010216

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of cancer education : the official journal of the American Association for Cancer Education, 2019. DOI 10.1007/s13187-017-1259-7

Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy Clinics in oncology., 2019.

Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC cancer, 2019. DOI 10.1186/s12885-019-5353-6

Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.4516

AUTHOR INDEX Asia-Pacific Journal of Clinical Oncology, 2019. DOI 10.1111/ajco.13229

A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of F-18-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR) Journal of Clinical Oncology, 2019. DOI 10.1200/JCO.2019.37.15_suppl.TPS5093

A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF F-18-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCERe EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY) Journal of Urology, 2019.

A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF (TC)-T-99M-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS) Journal of Urology, 2019.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019. DOI 10.5489/cuaj.6136